Larimar Therapeutics Inc (LRMR) vs. Its Peers: A Comparison

VLD Stock

Additionally, the 36-month beta value for LRMR is 0.88. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for LRMR is 37.09M and currently, short sellers hold a 10.54% ratio of that float. The average trading volume of LRMR on June 04, 2024 was 482.26K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

LRMR) stock’s latest price update

The stock price of Larimar Therapeutics Inc (NASDAQ: LRMR) has jumped by 14.25 compared to previous close of 8.00. Despite this, the company has seen a gain of 29.10% in its stock price over the last five trading days. globenewswire.com reported 2024-05-30 that BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria. START selection was based on demonstrated development program readiness, including the potential of nomlabofusp to address the serious and unmet medical needs in a rare neurodegenerative condition, alignment of chemistry, manufacturing, and controls (CMC) development timelines with clinical development plans, and a proposed communications plan where enhanced communication could accelerate pivotal study initiation and path to potential Biologics License Application (BLA) submission.

LRMR’s Market Performance

LRMR’s stock has risen by 29.10% in the past week, with a monthly rise of 20.11% and a quarterly drop of -19.96%. The volatility ratio for the week is 8.70% while the volatility levels for the last 30 days are 8.02% for Larimar Therapeutics Inc The simple moving average for the past 20 days is 20.20% for LRMR’s stock, with a 60.91% simple moving average for the past 200 days.

Analysts’ Opinion of LRMR

Many brokerage firms have already submitted their reports for LRMR stocks, with Leerink Partners repeating the rating for LRMR by listing it as a “Outperform.” The predicted price for LRMR in the upcoming period, according to Leerink Partners is $25 based on the research report published on April 03, 2024 of the current year 2024.

Citigroup, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $4.50. The rating they have provided for LRMR stocks is “Buy” according to the report published on November 17th, 2023.

Guggenheim gave a rating of “Buy” to LRMR, setting the target price at $12 in the report published on October 19th of the previous year.

LRMR Trading at 24.88% from the 50-Day Moving Average

After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.19% of loss for the given period.

Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 8.70%, as shares surge +17.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.78% upper at present.

During the last 5 trading sessions, LRMR rose by +29.10%, which changed the moving average for the period of 200-days by +127.93% in comparison to the 20-day moving average, which settled at $7.67. In addition, Larimar Therapeutics Inc saw 100.88% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LRMR starting from Flynn James E, who purchase 4,290,617 shares at the price of $8.74 back on Feb 16 ’24. After this action, Flynn James E now owns 6,151,406 shares of Larimar Therapeutics Inc, valued at $37,499,993 using the latest closing price.

Hamilton Thomas Edward, the Director of Larimar Therapeutics Inc, purchase 57,208 shares at $8.74 during a trade that took place back on Feb 16 ’24, which means that Hamilton Thomas Edward is holding 564,798 shares at $499,998 based on the most recent closing price.

Stock Fundamentals for LRMR

The total capital return value is set at -0.22. Equity return is now at value -26.75, with -24.56 for asset returns.

Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -6.79.

Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 2.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.99.

Conclusion

In conclusion, Larimar Therapeutics Inc (LRMR) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts